Mylan Escapes Novartis MS Drug Patent Suit
Mylan Pharmaceuticals Inc. was able to evade a patent suit from Novartis seeking to block generic versions of its multiple sclerosis drug Gilenya when a judge said Monday that Delaware federal...To view the full article, register now.
Already a subscriber? Click here to view full article